Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

New Delhi: Food regulator FSSAI has suspended the licence of Dior Pharmaceuticals for multiple violations at its nutraceutical factory. In a social media post on Thursday, FSSAI observed “serious non-compliances”…

Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

Additional chief secretary (ACS), health, Sumita Misra said of these, 12 arrests have been made by FDA, Gurugram, which has also busted multiple interstate counterfeit medicine syndicates, seized fake medicines…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

FSSAI Issues Prohibition Orders against FOLINEURO Syrup and Neuherbs TRUE VITAMIN over Misleading Claims

FSSAI Issues Prohibition Orders against FOLINEURO Syrup and Neuherbs TRUE VITAMIN over Misleading Claims

Pune Police Bust Illegal Bodybuilding Drug Racket, 5 Arrested; 50 Mephentermine Injections Seized In Major Crackdown

Pune Police Bust Illegal Bodybuilding Drug Racket, 5 Arrested; 50 Mephentermine Injections Seized In Major Crackdown

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

13 Years after Oxytocin Order, HC Seeks Compilance Status

13 Years after Oxytocin Order, HC Seeks Compilance Status